ڑ/HQYHUV GX G«FRU &RQVHLO GH IRQGDWLRQ 009 Mr Per Wold-Olsen* Chairman of MMV Board; former President of Human Health Intercontinental Region, Merck & Co., Inc., Middle East & Africa; former Member of Merck’s Management Committee; Chairman GN Store Nord A/S, Denmark; Board Member of Gilead Sciences Inc., USA; Chair of Oncopeptides AB, Sweden Dr David Reddy* CEO, MMV, Switzerland Dr David Brandling- Bennett Former Senior Advisor, Malaria, Bill & Melinda Gates Foundation, USA Mr Alan Court* Senior Adviser to the WHO Ambassador for Global Strategy, USA; former Director of the UNICEF Programme Division in New York; former Director of the UNICEF Supply Division in Copenhagen Prof. Sir Michael Ferguson Regius Professor of Life Sciences and Associate Dean for Research Strategy, University of Dundee, Scotland, UK Dr Winston Gutteridge Former Chief, Product R&D, Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Switzerland Ms Yuli Ismartono Co-founder and Managing Editor of AsiaViews; formerly with TEMPO magazine; Board Member of Nature Resources Governance Institute; the Coral Triangle Center; the Prestasi Junior Indonesia; and the Alternative Association of Southeast Asian Nations, Indonesia Mr Gabriel Jaramillo** Former General Manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland Dr Dominique Limet Former Chief Executive Ofcer, ViiV Healthcare, London, UK Ms Elizabeth Linder Executive Director, Beautiful Destinations, Senior Consulting Fellow, Chatham House Director’s Of ce; former Politics & Government Specialist, Facebook (California and EMEA region), based in USA/UK Dr Robert Newman Director, Aspen Management Partnership for Health, The Aspen Institute; Former Vice President and Global Head, TB Programs, Johnson & Johnson; former Director of Global Malaria Programme, WHO Ms Joy Phumaphi Co-Chair of the Independent Expert Review Group for Every Woman Every Child; Chair of the Global Leaders Council for Reproductive Health; Executive Secretary of African Leaders Malaria Alliance, USA Dr Wendy Sanhai Deloitte Consulting, LLP (Federal Strategy and Operations); Associate Professor (adj), Duke University, School of Medicine; former Senior Scientic Advisor, Ofce of the Commissioner, US Food and Drug Administration; former Senior Director, Global Regulatory Affairs, GSK, USA Dr Dennis Schmatz Former Vice President and Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan (now based in USA) Ambassador Dr Konji Sebati CEO, Innovative Pharmaceutical Association of South Africa (IPASA), Johannesburg, South Africa Deuxième ligne de gauche à droite Première ligne de gauche à droite * Membres du Comité Audit & Finance ** Président du Comité Audit & Finance 48 Medicines for Malaria Venture | Rapport annuel 2019
5
Embed
HQYHUV GX G«FRU 9.pdfBeautiful Destinations, Senior Consulting Fellow, Chatham House Director’s Of! ce; former Politics & Government Specialist, Facebook (California and EMEA
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
��HQYHUVڑ/GX�G«FRU����
&RQVHLO�GH�IRQGDWLRQ�009�
Mr Per Wold-Olsen*Chairman of MMV Board; former President of Human Health Intercontinental Region, Merck & Co., Inc., Middle East & Africa; former Member of Merck’s Management Committee; Chairman GN Store Nord A/S, Denmark; Board Member of Gilead Sciences Inc., USA; Chair of Oncopeptides AB, Sweden
Dr David Reddy*CEO, MMV, Switzerland
Dr David Brandling-BennettFormer Senior Advisor, Malaria, Bill & Melinda Gates Foundation, USA
Mr Alan Court*Senior Adviser to the WHO Ambassador for Global Strategy, USA; former Director of the UNICEF Programme Division in New York; former Director of the UNICEF Supply Division in Copenhagen
Prof. Sir Michael FergusonRegius Professor of Life Sciences and Associate Dean for Research Strategy, University of Dundee, Scotland, UK
Dr Winston GutteridgeFormer Chief, Product R&D, Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Switzerland
Ms Yuli IsmartonoCo-founder and Managing Editor of AsiaViews; formerly with TEMPOmagazine; Board Member of Nature Resources Governance Institute; the Coral Triangle Center; the Prestasi Junior Indonesia; and the Alternative Association of Southeast Asian Nations, Indonesia
Mr Gabriel Jaramillo**Former General Manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland
Dr Dominique LimetFormer Chief Executive Of! cer, ViiV Healthcare, London, UK
Ms Elizabeth LinderExecutive Director, Beautiful Destinations, Senior Consulting Fellow, Chatham House Director’s Of! ce; former Politics & Government Specialist, Facebook (California and EMEA region), based in USA/UK
Dr Robert NewmanDirector, Aspen Management Partnership for Health, The Aspen Institute; Former Vice President and Global Head, TB Programs, Johnson & Johnson; former Director of Global Malaria Programme, WHO
Ms Joy Phumaphi Co-Chair of the Independent Expert Review Group for Every Woman Every Child; Chair of the Global Leaders Council for Reproductive Health; Executive Secretary of African Leaders Malaria Alliance, USA
Dr Wendy SanhaiDeloitte Consulting, LLP (Federal Strategy and Operations); Associate Professor (adj), Duke University, School of Medicine; former Senior Scienti! c Advisor, Of! ce of the Commissioner, US Food and Drug Administration; former Senior Director, Global Regulatory Affairs, GSK, USA
Dr Dennis SchmatzFormer Vice President and Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan (now based in USA)
Ambassador Dr Konji SebatiCEO, Innovative Pharmaceutical Association of South Africa (IPASA), Johannesburg, South Africa
Deuxième ligne de gauche à droite Première ligne de gauche à droite
* Membres du Comité Audit & Finance ** Président du Comité Audit & Finance
48 Medicines for Malaria Venture | Rapport annuel 2019
&RQVHLO�GH�IRQGDWLRQ�GH�009�1RUWK�$PHULFD�,QF�Ms Sylvie Fonteilles-Drabek Chair of MMV North America Board ; General Counsel and Executive Vice President, MMV, Switzerland
Mr Andrea BuscagliaChief Financial Of! cer, MMV, Switzerland
Mr Alan CourtSenior Adviser to the WHO, Ambassador for Global Strategy, USA; former Director of the UNICEF Programme Division in New York; former Director of the UNICEF Supply Division in Copenhagen
Ms Andrea LucardExecutive Vice President, Corporate Affairs, MMV, Switzerland
Dr Dennis SchmatzFormer Vice President and Head of Tsukuba Research Institute, Merck-Banyu Research Laboratories, Japan (now based in USA)
&RPLW«�FRQVXOWDWLI�GڑH[SHUWV�VFLHQWLஊ�TXHV��(6$&��Dr John PottageCo-Chairman MMV ESAC (Drug Development); Chief Scienti! c and Medical Of! cer, ViiV Healthcare, USA
Dr Michael WittyCo-Chairman MMV ESAC (Drug Discovery); Drug Discovery Consultant and former Vice President P! zer R&D, UK
Dr Aileen Allsop Former Vice President for Science Policy, R&D, AstraZeneca, UK
Prof. Thomas Baillie Dean Emeritus, School of Pharmacy, University of Washington, USA
Dr Tesfaye BiftuDistinguished Professor, National Institute of Pharmaceutical Sciences, Adama Science and Technology University, Ethiopia
Sir Simon CampbellFormer Senior Vice President for WW Discovery, P! zer, organic chemist, UK
Dr Anne Cooper Programme Director, Sosei Heptares, UK
Prof. Brian Cox Professor of Pharmaceutical Chemistry, University of Sussex, School of Life Sciences, UK
Ms Delese Mimi Darko CEO, Safety Monitoring & Clinical Trials Division, Food and Drugs Authority, Ghana
Dr Michael Dunne Chief Medical Of! cer, Durata Therapeutics, USA
Prof. Daniel GoldbergProfessor and Co-Chief, Division of Infectious Diseases, Department of Medicine, Washington University, USA
Dr Tim HammondIndependent Pharmaceutical Preclinical Safety Consultant at Preclinical Safety Consulting Ltd, UK
Dr Monica Hemben EimunjezeDirector, Registration & Regulatory Affairs Directorate, National Agency for Food and Drug Administration and Control, Nigeria
Dr Laurent HennequinResearch Director, Galderma R&D by Nestlé Skin Health/Galderma R&D, Sophia Antipolis, France
Prof. Dennis Kyle Director, Center for Tropical and Emerging Global Diseases, University of Georgia, USA
Dr Marcus Lacerda Public Health Specialist, Fiocruz, Brazil
Prof. John Lambert Chief Medical Of! cer, Global Head Medical Affairs and Consulting, PAREXEL International – Early Phase, UK
Dr Mary Mader Research Fellow, Discovery Chemistry Research and Technologies, Eli Lilly and Company, USA
Dr George MooneyKGM Pharma Consulting LLC, USA
Dr Robert Riley Executive Vice President, Drug Discovery, Evotec, UK
Dr Esperança SeveneSenior Research Fellow, Manhiça Health Research Centre, Mozambique
Prof. Dennis Shanks Director, Australian Defence Force Malaria and Infectious Disease Institute, Australia
Dr Peter Siegl Siegl Pharma Consulting, USA
Dr Shailja SinghAssociate Professor, Special Centre for Molecular Medicine, Jawaharlal Nehru University, India
Dr Sodiomon Sirima Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso
Dr John Surtees Managing Partner, Berzelius Integrated Solutions, Belgium
Dr Klaus Urbahns Head of Discovery and Development Technologies at Merck Group, Germany
Dr Elizabeth VadasPresident, InSciTech Inc. Canada
Prof. Stephen WardDeputy Director, Liverpool School of Tropical Medicine, UK
Dr Takeshi Yura Vice President Medicinal Chemistry, Jubilant Biosys Ltd, India
&RPLW«�FRQVXOWDWLI�GڑH[SHUWV�$FFHVV��3URGXFW�0DQDJHPHQW��$30$&�Dr Richard SteketeeChairman MMV APMAC; Deputy Director, US President’s Malaria Initiative, USA
Dr Martin De Smet Coordinator the Malaria Working Group of Médecins Sans Frontières
Dr Graciela DiapAssociate Staff of DNDi and FACT Medical Coordinator, Spain
Dr Susanna Hausmann-MuelaChief Program Of! cer, Botnar Foundation, Switzerland
Dr Corine Karema Swiss TPH, Switzerland; Malaria Expert on Global Fund Technical Review Panel; former Director NMCP, Rwanda
Ms Maeve Magner Supply Chain Expert, USA/Ireland
Dr Wilfred MbachamFellow CAS/AAS, Chair of Dept. of Physiology and Biochemistry, University of Yaoundé, Cameroon
Dr Kamini Mendis Independent Consultant in Malaria and Tropical Medicine, Sri Lanka
Dr Suerie MoonCo-Director, Global Health Centre, The Graduate Institute of Geneva, Switzerland
Dr Ric PriceProfessor of Global Health at the Menzies School of Health Research (Australia), Professor of Tropical Medicine at the Centre of Tropical Medicine, University of Oxford, UK
Dr Melanie RenshawChief Technical Advisor, ALMA, and Co-Chair, Roll Back Malaria CRSPC, Switzerland
Dr Frank Richards Jr. M.D. Director, River Blindness Elimination Program, Lymphatic Filariasis Elimination Program, and Schistosomiasis Control Program, Carter Center, USA
Dr Brenda WaningVice-Chairman of MMV APMAC; Chief, Global Drug Facility, Stop TB Partnership, Switzerland
&RPLW«�GH�V«FXULW«�J«Q«UDOHDr Stephan DuparcCo-Chairman MMV Global Safety Board; Chief Medical Of! cer, MMV, Switzerland
Dr Trevor GibbsCo-Chairman MMV Global Safety Board; Independent Consultant; former Senior Vice President, Pharmacovigilance & Medical Governance,GSK, UK
Prof. Tim HammondPharmaceutical Preclinical Safety Consultant, UK
Prof. Pieter JoubertClinical Pharmacology Consultant, UK
Rédaction Elizabeth Poll & Claire-Marie Germain, MMVTraduction Isabelle ParkDesign ComStone - Pierre Chassany, Genève, Suisse Impression Atar Roto Press SA, Genève, SuisseLithographie Catherine Vogt, Carouge, SuissePhotographes BMC St Jude (pp. 31 & 35–36), Pierre Chassany pour MMV (pp. 2 & 19), ITN Production (p. 29b),
Diaka T Jules/ Alain Mugoto, CARAMAL project (p. 27), Toby Madden/Transaid (Couvertures, pp. 13, 15,17, 20 & 25), Kathryn Malhotra pour PMI Impact Malaria (p. 22–23), Sergey-73/Shutterstock (p. 29a), Nicolas Spuhler (pp. 50–51), Damien Schumann (p. 26) et Anna Wang/MMV (p. 33).
Photos de portraits fournies par les personnes interviewées. Photos des "Principales réalisations" (pp. 8–9): BMC St Jude, Marco Corsi/Sigma-Tau, Steve Jurvetson sous licence CC BY 2.0, Toby Madden pour Transaid et MMV, Maud Majeres Lugand, Antje Mangelsdorf, Elizabeth Poll, Damien Schumann.
MMV est également reconnaissante pour le soutien reçu de particuliers.